Share This Article

Facebook LinkedIn
Twitter Reddit
Print Email
Pinterest Gmail
Yahoo
Money Morning
×
Login Archives Your Team About Us FAQ
[mmpazkzone name="azk58712-mobile-nav" network="9794" site="307044" id="222451" type="5"]
  • Subscribe
Enter stock ticker or keyword
×
[mmpazkzone name="azk58712-mobile-sticky" network="9794" site="307044" id="222451" type="5"]
Join 100,000+ Like-Minded Investors Today
Twitter
Tags: Hot stocks

Why Marijuana Stock GW Pharmaceuticals (Nasdaq: GWPH) Is Flying High

By Diane Alter, Contributing Writer, Money Morning • April 23, 2014

View Comments

Start the conversation

Leave a Reply Click here to cancel reply.

You must be logged in to post a comment.

GW Pharmaceuticals PLC (Nasdaq: GWPH) stock is up more than 50% over the past two days thanks to a bullish and bold call from Morgan Stanley.

The investment firm on Tuesday issued an "Overweight" rating on the U.K.-based company, a leader in cannabis-based drugs, and set an aggressive $103 price target on shares, more than double Monday's close.

gwph stockMorgan Stanley's optimistic rating and sky-high price target sent shares up a whopping 32.19% to $60.86 on Tuesday. Volume was extremely heavy, with some 6,752,000 shares changing hands - more than thirteen times the stock's three-month average daily volume of 515,831.

Also stoking GWPH stock Tuesday were comments from CNBC's Jim Cramer.

"Shocked" by Morgan Stanley's daring call, Cramer said it was nonetheless a "timely" recommendation given the current marijuana stock craze. Cramer added the stock will quickly reach Morgan Stanley's target price and said GW is the top play in today's current marijuana stock obsession.

GW's strong stock momentum carried through to Wednesday, with shares rising more than 20% to $73.33 intraday. By mid-day more than 3 million shares had traded.

Adding fuel to GW's colossal gains Wednesday were bullish options activity and potential takeover chatter.

But, more on Morgan Stanley's call...

GW's (Nasdaq: GWPH) Promising Drug Pipeline

Morgan Stanley sees potential in GW's unique product pipeline and its "novel platform." The firm is particularly keen on GW's epilepsy drug Epidiolex, which has shown notable promise in a small yet growing set of data.

Epidiolex could generate worldwide sales of $1.35 billion and will make up 90% of GW's peak revenue, according to Morgan Stanley.

Additionally, U.S. sales of GW's Sativex, a treatment for multiple sclerosis (MS) spasticity and cancer pain, should also grow substantially, the firm predicted. "GW has multiple additional drugs in early stage development... that are not currently part of our valuation, but could be upside drivers over time," Morgan Stanley wrote in Tuesday's note to clients.

Other drugs in development include therapies for ulcerative colitis, schizophrenia, type 2 diabetes, and glioma (tumors that start in the brain or spine).

While Morgan Stanley touted GW's pharmaceutical offerings, the firm also highlighted GW's focus on medical marijuana treatments. Of particular mention was the uniform blend of elements and chemicals GW uses to create safe, effective medical marijuana in climate-controlled standard indoor glasshouses.

Indeed, GW's demonstrated consistency and predictability of doses has garnered the company an elevated status in the medical marijuana industry. Morgan Stanley noted GW has a stellar consistency standard and develops its drugs with strict adherence to FDA dosing guidelines.

Other Wall Street firms offering opinions on GW include Bank of America, Piper Jaffray, and Lerrink Swann. The consensus view among the trio is that the stock is a "Buy."

GWPH Stock: The Best "Pot" Play and Beyond

Undeniably, marijuana stocks have been on fire in 2014, amid fresh legalized recreational use in Colorado and Washington. Moreover, 21 states and Washington, D.C., have approved marijuana use for medicinal and therapeutic purposes.

As a result, a number of "pot" penny stocks have soared. Hemp Inc. (OTCMKTS: HEMP), Cannabis Science Inc. (OTCMKTS: CBIS), and Medical Marijuana Inc. (OTCMKTS: MJNA) have enjoyed gains of 559%, 255%, and 119% respectively.

But the best profit play in the legalized pot industry is indeed GWPH, according to Money Morning Defense & Tech Specialist Michael A. Robinson.

Robinson cited GWPH's prowess back in March, for the same reasons Morgan Stanley noted Tuesday.

"With its solid science, multiple uses for its main cannabis-based biotech product, and strong alliances with global drug leaders, GW Pharmaceuticals should leave investors rewarded," Robinson wrote.

In fact, Robinson detailed for investors why GWPH stock is such a great profit play in this field. Go here for the full story on GW Pharmaceuticals stock.

Related Articles:

  • Medical Marijuana:

    Details by State
  • Schaeffer's Research:

    Schaeffer's Option Center
  • CNBC:
    Cramer: This 'Cannabis' Stock Will Quickly Double
ABOUT MONEY MORNING

Money Morning gives you access to a team of market experts with more than 250 years of combined investing experience – for free. Our experts – who have appeared on FOXBusiness, CNBC, NPR, and BloombergTV – deliver daily investing tips and stock picks, provide analysis with actions to take, and answer your biggest market questions. Our goal is to help our millions of e-newsletter subscribers and Moneymorning.com visitors become smarter, more confident investors.

QUICK LINKS
About Us How Money Morning Works FAQs Contact Us Search Article Archive Your Team Text Messaging Terms of Use
TOPICS
AI Investing Best Stocks to Buy Stock Forecasts Stocks to Sell Now Technology Stocks Best REITs to Buy Now IPO Stocks Penny Stocks Dividend Stocks Cryptocurrencies How to Trade Options Best Trades to Make Now Options Trading Strategies Weekly Trade Recommendations Income Investing Guide Retirement Articles Special Investing Reports Meet Our Experts
PREMIUM SERVICES
Money Map Press Home Fast Fortune Club Microcurrency Trader Rocket Wealth Initiative Quantum Data Profits Darknet Alpha Accelerators Brutus Alerts Resource Traders Alliance Rob Roy Trader Long-Term Equity Profits

© 2023 Money Morning All Rights Reserved. Protected by copyright of the United States and international treaties. Any reproduction, copying, or redistribution (electronic or otherwise, including the world wide web), of content from this webpage, in whole or in part, is strictly prohibited without the express written permission of Money Morning.

Address: 1125 N Charles St. | Baltimore, MD, 21201 | USA | Phone: 888.384.8339 | Disclaimer | Sitemap | Privacy Policy | Whitelist Us | Do Not Sell or Share My Personal Information